Promising clinical results for heavily pretreated patients with colorectal cancer
Patients with KRASG12C-mutant colorectal cancer treated with Adagrasib – a KRASG12C inhibitor that irreversibly and selectively binds KRASG12C, locking it, when in active state. In this MEDtalk. In this MEDtalk Jared Weiss, oncologist, presents the promising results of adagrasib treatment.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
